5Ichiki T, Takeda K, Tokunou T, et al. Downregulation ofangiotensin Ⅱ type lreceptor by hydrophobic 3 hydrosy-3-methylglutaryl coenxyme A reductase inhibitors in vascular smooth muscle eells[J]. Arterioscler Thromb Vase Biol, 2001,21 (12):1896- 1901.
6Lecian D, Demova H, Lodererova A, et al. Renal effects of 'HMG- CoA reductase inhibition in a rat model of chronic inhibition of ni trie oxide synthesis[J]. Kidne'y Blood Press Res, 2006,29 : 135- 143.
8Patti G, Nusca A, Chello M, et al. Usefuless of statin pretreatment to prevent contrast-induced nephropathy and to improve long term outcome in patients undergoing percutaneous coronary intervention[J]. Am J Cardiol, 2008,101 : 279-285.
3Johansen O,Brekket M,Stromme JH,et al.Myocardial damage during percutaneous transluminal coronary angioplasty as evidented by troponin T measurements[J].Eur Heart J,1998,19:112-117.
4Amoroso G,van Veldhuisen DJ,Tio RA,et al.Pathophysiology of vascular endothelium and circulation platelets:implications for coronary revascularisation and treatment[J].Int J Cardiol,2001,79:265-275.
5Bavry AA,Mood GR,Kumbhani DJ,et al.Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome:a systematic review of randomized trials[J].Am J Cardiovasc Drugs,2007,(2):135-141.
6Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibrie acid derivative [ J]. Am J Cardiovase Drugs,2003, 3:169 - 178.
7Plenge JK, Hemandez TL, Weil KM, et al. Simvastatin lowers C-reac-tive protein within 14days:an effect independent of low-density lipo-protein cholesterol reduction [ J ]. Circulation, 2002,106 ( 12 ) : 1447 - 1452.
8Aspelin P.Nephrotoxicity and the role of contrast media.Radiat Med,2004,22:377-378.
10Taylor AJ,Hotehkiss D,Morse RW,et al.PREPARED:Preparation for Angiography in Renal Dysfunction:a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction.Chest,1998,114:1570-1574.
6Hovind P, Rossing P, Johnson R J, et al. Serum uric acid as a new player in the development of diabetic nephropathy[J]. J Ren Nutr, 2011, 21(1): 124-127.
7Boratyńska M, Karbowska A, Klinger M, et al. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients[J]. Transplant Proc, 2010, 42(10): 4074-4077.
8Ho W J, Tsai W P, Yu K H, et al. Association between endothelial dysfunction and hyperuricaemia[J]. Rheumatology, 2010, 49(10): 1929-1934.
9Long C L, Qin X C, Pan Z Y, et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia[J]. J Hypertens, 2008, 26(12): 2326-2338.
10Edwards N L. The role of hyperuricemia in vascular disorders[J]. Curr Opin Rheumatol, 2009, 21(2): 132-137.
